STOCK TITAN
  1. Home
  2. News
  3. IDYA

Ideaya Biosciences Inc - IDYA STOCK NEWS

IMPACT
SENTIMENT
IDYA : Nasdaq
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma
clinical trial
IMPACT
SENTIMENT
IDYA : Nasdaq
IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma
clinical trial
IMPACT
SENTIMENT
IDYA : Nasdaq
IDEAYA Biosciences Announces Development Candidate Nomination of a Werner Helicase Inhibitor in Collaboration with GSK and Investor R&D Day
IMPACT
SENTIMENT
IDYA : Nasdaq
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IMPACT
SENTIMENT
IDYA : Nasdaq
IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer
clinical trial
IMPACT
SENTIMENT
IDYA : Nasdaq
IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations
clinical trial
IMPACT
SENTIMENT
IDYA : Nasdaq
IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid Tumors
clinical trial
IMPACT
SENTIMENT
IDYA : Nasdaq
IDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations Events
conferences
IMPACT
SENTIMENT
IDYA : Nasdaq
IDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 (IDE705)
clinical trial
IMPACT
SENTIMENT
IDYA : Nasdaq
IDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma
clinical trial
Stock IDYA logo
Ideaya Biosciences Inc
Nasdaq:IDYA

IDYA Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link

About IDYA

ideaya biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting dna damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. founded in 2015, ideaya’s investors include 5am ventures (5am), canaan partners (canaan), celgene, wuxi healthcare ventures (wuxi), novartis institute of biomedical research, and alexandria real estate. the company has assembled a world-class drug discovery team and scientific advisory board (sab) that is represented by a nobel laureate and three members of the national academy of sciences. ideaya is located in south san francisco and la jolla, california.